Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats

  title={Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory Depressant Effect of Norbuprenorphine in Rats},
  author={Ashraf Yassen and Jingmin Kan and Erik Olofsen and Ernst Suidgeest and Albert Dahan and Meindert Danhof},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  pages={598 - 607}
The objective of this investigation was to characterize the pharmacokinetic-pharmacodynamic (PK-PD) correlation of buprenorphine's active metabolite norbuprenorphine for the effect on respiration in rats. Following i.v. administration in rats (dose range 0.32–1.848 mg), the time course of the concentration in plasma was determined in conjunction with the effect in ventilation as determined with a novel whole-body plethysmography technique. The PK of norbuprenorphine was best described by a… 

Figures and Tables from this paper

Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats
The SC administration of Simbadol™ was characterized by prolonged absorption half-life and sustained plasma concentrations yielding long-lasting antinociception (≥ 24 hours) when compared with the IV and OTM routes.
Incorporating receptor theory in mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling.
An overview of recent developments in incorporating receptor theory in PK-PD modeling with a specific focus on the identifiability of these models is provided.
Pharmacokinetic and pharmacodynamic analysis in anesthesia : a modeling odyssey
The development of an open source web application for Bland-Altman analysis of comparison data, which is able to take into account both intra- and interindividual variability is described.
Reduced Pupil Diameter in Volunteers on Stable Buprenorphine Maintenance Therapy with Telaprevir: a Drug-Drug Interaction Involving P-Glycoprotein at the Blood-Brain Barrier?
The BUP-related respiratory effects in mice were significantly increased in relation to reduced NBUP efflux at the BBB, with either P-glycoprotein pharmacological inhibition or gene disruption, supporting the notion that telaprevir and BUP/naloxone can be safely co administered.
Pregnancy Increases Norbuprenorphine Clearance in Mice by Induction of Hepatic Glucuronidation
The data suggest that the increased systemic CL of NBUP in pregnant mice is likely caused by an induction of hepatic Ugt expression and activity, and provides a basis for further mechanistic analysis of pregnancy-induced changes in the disposition ofNBUP and drugs that are predominately and extensively metabolized by Ugts.
Mechanism-based pharmacodynamic modeling.
In this chapter, commonly used mechanistic pharmacodynamic models are presented with respect to their important features, operable equations, and signature profiles and literature examples showcasing the utility of these models to adverse drug events are highlighted.
P-Glycoprotein Is a Major Determinant of Norbuprenorphine Brain Exposure and Antinociception
P-glycoprotein-mediated efflux influences brain access and antinociceptive, but not the respiratory, effects of norbuprenorphine.
In Utero Exposure to Norbuprenorphine, a Major Metabolite of Buprenorphine, Induces Fetal Opioid Dependence and Leads to Neonatal Opioid Withdrawal Syndrome
Findings support the possibility that NorBUP contributes to fetal opioid dependence and NOWS following maternal buprenorphine treatment during pregnancy, using a rat model of NOWS.
Plasma concentrations of buprenorphine following a single subcutaneous administration of a sustained release formulation of buprenorphine in sheep.
A long lasting potential analgesic plasma level of buprenorphine is attained following a single subcutaneous injection of 0.1 mg/kg BW of SR bupenorphine in sheep, however the effective analgesic Plasma threshold still needs to be determined in sheep.
Buprenorphine metabolites, buprenorphine-3-glucuronide and norbuprenorphine-3-glucuronide, are biologically active.
Both glucuronide metabolites of buprenorphine are biologically active at doses relevant to metabolite exposures, which occur after bupenorphine, and activity of the glucuronides may contribute to the overall pharmacology of buPrenorphines.


Mechanism-Based Pharmacokinetic-Pharmacodynamic Modeling of the Respiratory-Depressant Effect of Buprenorphine and Fentanyl in Rats
For fentanyl, unrealistically high estimates of the rate constants for receptor association and dissociation were obtained, indicating that hysteresis is caused solely by biophase distribution kinetics, consistent with fentanyl's fast receptor association/dissociation kinetics in vitro.
Pharmacokinetic-Pharmacodynamic Modeling of the Antinociceptive Effect of Buprenorphine and Fentanyl in Rats: Role of Receptor Equilibration Kinetics
The findings of this study show that the rate-limiting step in the onset and offset of buprenorphine's antinociceptive effect is distribution to the brain.
The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model.
Analysis of the data on the basis of a previously postulated, mechanism-based pharmacokinetic-pharmacodynamic model for synthetic opioids revealed that the low in vivo potency of GR90291 can be explained by a low affinity to the mu-opioid receptor in combination with a poor brain penetration.
Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.
We propose a model of drug pharmacodynamic response that when integrated with a pharmacokinetic model allows characterization of the temporal aspects of pharmacodynamics as well as the
Characterization of the pharmacokinetics of buprenorphine and norbuprenorphine in rats after intravenous bolus administration of buprenorphine.
  • S. Gopal, T. Tzeng, A. Cowan
  • Biology, Medicine
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2002
Kinetics of respiratory depression in rats induced by buprenorphine and its metabolite, norbuprenorphine.
The results suggest that the respiratory depression induced by NBN may be mediated by opioid mu receptors in the lung rather than in the brain, and that it is likely that buprenorphine-induced depression was rapidly reduced after i.v. administration.
Buprenorphine is protective against the depressive effects of norbuprenorphine on ventilation.
Pharmacokinetic analysis of enterohepatic circulation of buprenorphine and its active metabolite, norbuprenorphine, in rats.
It was suggested that this increase in the proportion of NBN-Glu in bile observed after one enterohepatic cycling of BN may be due to the first-pass metabolism in the liver.
Clinical actions of fentanyl and buprenorphine. The significance of receptor binding.
Findings offer pharmacodynamic explanations for the differences in fentanyl and buprenorphine analgesic response profiles and suggest how binding interactions might be applied to therapeutic use.
Characterization of the pharmacodynamic interaction between parent drug and active metabolite in vivo: midazolam and alpha-OH-midazolam.
It is concluded that pharmacodynamic parameters of single drugs can be estimated after a combined administration when a mechanistically valid interaction model is applied.